Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Trending in Altmetric
This article is in the top 10% of similar research outputs scored by Altmetric,
a service which tracks the online attention articles have received.
Abstract: Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy and safety of bosutinib versus imatinib for first-line treatment of chronic-phase CML. Methods In this ongoing, multinational, phase III study, 536 patients with newly diagnosed ...
Philadelphia Chromosome (4), Chronic BCR-ABL Positive Myelogenous Leukemia (2), Diarrhea (1), more mentions